The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 3575 -3585
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiao, Y. Q.
Right arrow Articles by Henson, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, Y. Q.
Right arrow Articles by Henson, P. M.

Transcriptional and Translational Regulation of TGF-β Production in Response to Apoptotic Cells1

Yi Qun Xiao*, Celio G. Freire-de-Lima*,{dagger}, William P. Schiemann§, Donna L. Bratton*, R. William Vandivier{ddagger} and Peter M. Henson2,*

* Program in Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206; {dagger} Instituto de Biofísica Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; and {ddagger} Division of Pulmonary Sciences and Critical Care Medicine and § Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, CO 80045


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Interaction between apoptotic cells and phagocytes through phosphatidylserine recognition structures results in the production of TGF-β, which has been shown to play pivotal roles in the anti-inflammatory and anti-immunogenic responses to apoptotic cell clearance. Using 3T3-TβRII and RAWTβRII cells in which a truncated dominant-negative TGF-β receptor II was stably transfected to avoid autofeedback induction of TGF-β, we investigate the mechanisms by which TGF-β was produced through PSRS engagement. We show, in the present study, that TGF-β was regulated at both transcriptional and translational steps. P38 MAPK, ERK, and JNK were involved in TGF-β transcription, whereas translation required activation of Rho GTPase, PI3K, Akt, and mammalian target of rapamycin with subsequent phosphorylation of translation initiation factor eukaryotic initiation factor 4E. Strikingly, these induction pathways for TGF-β production were different from those initiated in the same cells responding to LPS or PMA.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Deletion of apoptotic cells in vivo involves recognition of surface changes on the cells leading to their ingestion by unique phagocytic mechanisms – a process that we have termed efferocytosis (1, 2, 3, 4, 5). Accompanying this recognition, whether or not the apoptotic cell is actually engulfed by the phagocyte, is the generation of anti-inflammatory mediators (6, 7, 8, 9) and the establishment of a generally anti-inflammatory and anti-immunogenic local environment. We have earlier suggested that TGF-β is a major mediator of this response, and that a number of secondary anti-inflammatory effects result from the autocrine/paracrine actions of the active TGF-β produced.

The TGF-β family comprises more than 60 structurally related growth and differentiation factors that play important roles in regulation of numerous physiological processes, including cell proliferation, differentiation, apoptosis, early embryonic development, and extracellular matrix protein synthesis (10, 11, 12, 13, 14). TGF-β exerts its effects through a heteromeric receptor complex consisting of type I and II transmembrane serine/threonine kinase receptors (15). The most well-defined signaling pathways of TGF-β are through Smad family members and the MAPK family (11, 16, 17). In mammals, there are three isoforms of TGF-β (TGF-β1, β2, and β3), which are structurally identical and have similar bioactivities. TGF-β may be released as a result of apoptotic cell interaction with inflammatory cells, such as macrophages, but also by structural cells such as airway epithelial cells, endothelial cells, and fibroblasts.

During apoptosis, a number of changes occur on the plasma membrane that contribute to recognition of these dying cells by potential phagocytes. One of these is phosphatidylserine (PS),3 normally restricted to the inner membrane leaflet, but exposed on the outer leaflet as a consequence of loss of membrane phospholipid asymmetry during apoptosis (18, 19). There is considerable evidence to support a major role for recognition of this PS in the production of TGF-β and the anti-inflammatory effects of apoptotic cells (6, 8, 9, 20, 21, 22). Thus, in our previous studies, we have demonstrated that interaction of phagocytes with apoptotic cells through PS results in production of the active TGF-β both in vitro and in vivo (6, 8, 9). Its anti-inflammatory effect and TGF-β dependency have been shown in the inflamed lung instilled with apoptotic Jurkat cells (8) and anti-immunogenic effects likewise following PS administration during an adaptive immune response (22).

The objective of this study was to determine the signal pathways involved in the generation of TGF-β by apoptotic cell stimulation. Unfortunately, the receptor(s) that recognizes PS (PS recognition structures (PSRS)) that is responsible for this effect is unknown. A number of recent papers have described candidate PS receptors (23, 24, 25, 26, 27), but only one of these (28) was studied for its potential induction of TGF-β. In addition, a number of bridge molecules that bind apoptotic cell PS and link this to various phagocyte receptors have been described (29, 30, 31, 32, 33). At this point, it is not clear which of these are involved in TGF-β synthesis and release. Accordingly, the experiments in this study used whole apoptotic cells as stimulus. In addition, to avoid the complexity of assay systems that may be confounded by the presence of both apoptotic as well as responder cells, we have included studies with an IgM mAb (mAb217) created earlier by immunizing with macrophages that were active in PS recognition (34). This Ab was used originally to identify a candidate PS receptor that was originally termed PSR (34), but is now known not to serve this function (35, 36), but rather to belong to the Jumonji family of proteins (JMJD6) and to act as a histone demethylase (37). We now interpret this original identification as due to nonspecific binding of the Ab in the phage display. Nonetheless, this mAb217 Ab binds to and activates macrophages and other potential phagocytes, mimicking exactly the effects of PS exposed on apoptotic cells in contributing to uptake, and the generation of anti-inflammatory mediators, including TGF-β (7, 22, 38). Accordingly, the studies reported in this work have used intact apoptotic cells and mAb217 to stimulate macrophages and fibroblasts for TGF-β production. Including the Ab stimulation allows us to bypass any confusion that may result from contribution of signaling molecules from the apoptotic cells themselves, as well as to provide a coordinated stimulus, where needed, to avoid the issue of the time it takes individual apoptotic cells and responding cells to interact. TGF-β production may be regulated at many steps, including transcription, translation, secretion, and especially activation in the extracellular environment. It is likely that apoptotic cell stimulation can alter each of these steps. However, in this study, we have focused on only the first two. The results suggest regulation of both transcription and translation by pathways that differ substantially from those used by other stimuli of TGF-β synthesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Abs and reagents

TGF-β1 was from R&D Systems. LPS (Escherichia coli 0111:B4) was from List Biological Laboratories. SB 203580, PD 98059, JNK inhibitor II, wortmannin, LY 294002, rapamycin, and protease inhibitor mixture set I were from Calbiochem-Novabiochem. Actinomycin D and cycloheximide were from Sigma-Aldrich. Gene-specific relative RT-PCR kit was from Ambion. Advantage RT-for-PCR kit was from BD Biosciences. Lipofectamine Plus reagent was from Life Technologies. Rho activation assay kit and recombinant C3 transferase were from Cytoskeleton. Phospho-ERK (E-4), ERK-2 (K 23), p38 (c-20), TGF-β (V)-G, phospho-eukaryotic initiation factor 4E (eIF4E), and total eIF4E Abs were from Santa Cruz Biotechnology. Anti-p38 MAPK phospho-specific Ab, phospho-SAPK/JNK (Thr183/Tyr185), phospho-Akt, β-actin, phospho-mammalian target of rapamycin (mTOR), and mTOR Abs were from Cell Signaling Technology. Generation of IgM mAb217 and its IgM control was described by Fadok et al. (34). Induction of apoptotic Jurkat cells and characterization of apoptotic and control cells were described previously (7).

Stable transfection of truncated TGF-β receptor II

Stable cell lines of 3T3TβRII, 3T3V, RAWTβRII, and RAWV cells were made by transfecting truncated TGF-β receptor II or empty vector. Briefly, pcDNA3.1 plasmids with or without MYC-tagged truncated TGF-β receptor II sequence were transfected into 3T3-L1 and RAW 264 cells using Lipofectamine Plus reagent, according to the manufacturer’s instructions. Seventy-two hours after transfection, the cells were incubated in the fresh medium containing 500 µg/ml G418 for 4 wk. Cell colonies resistant to G418 were isolated and screened by limited dilution.

Cell culture and ELISA

The cells (5.0 x 105 cells/well) were plated in each well of a 24-well tissue culture plate and incubated overnight in DMEM supplemented with 10% FBS, L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 µg/ml) under a humidified 10% (3T3 cells) or 5% (RAW cells) CO2 atmosphere at 37°C before stimulation for 18 h in the serum-free DMEM. Total TGF-β in cell culture supernatant was quantitated by ELISA, according to the instructions of the manufacturer (ELISA Tech).

Transient cell transfection and reporter gene assays

TGF-β-responsive luciferase reporter pSBE-Luc (Smad-binding elements (SBE)) was transfected into 3T3TβRII and 3T3V cells using Lipofectamine Plus reagent, according to the manufacturer’s instructions. pSV-β-galactosidase vector (Promega) was cotransfected as internal control to measure differences in transfection efficiency. Luciferase and β-galactosidase activities were measured 18 h after TGF-β stimulation using Luciferase Assay System (Promega) and Galacto-Light (Tropix), respectively. Dominant-negative RhoA N19 and constitutively active RhoA V14 (provided by J. Hu, National Jewish Medical and Research Center, Denver, CO) and empty vector were transiently transfected into 3T3TβRII cells using Lipofectamine Plus reagent. After 48 h, the cells were stimulated with mAb217 for 30 min, and total cell lysates were analyzed using immunoblotting for phospho-eIF4E and phospho-Akt.

Relative quantitative RT-PCR of TGF-β mRNA

Total RNA was isolated from cultured cells using TRIzol reagent (Life Technologies). The concentration and purity of RNA were evaluated by spectrophotometry at 260 and 280 nm. Reverse transcription was conducted for 60 min at 42°C with 1 µg of total RNA using Advantage RT-for-PCR kit (BD Biosciences). TGF-β mRNA level was determined using relative quantitative RT-PCR kit (Ambion). The cDNA was denatured for 5 min at 94°C, and the amplification was achieved in a temperature cycler (PerkinElmer GeneAmp PCR System 2400) by 24 cycles of temperature (94°C for 30 s, 57°C for 30 s, and 72°C for 30 s), followed by a 7-min final extension at 72°C. A total of 5 µl of each PCR sample was loaded on a 1.5% agarose gel stained with ethidium bromide. The relative fluorescence of TGF-β vs 18S rRNA was analyzed by densitometry.

RhoA activation assay

The 3T3TβRII (5 x 106 cells) cells were plated in 10-cm tissue culture dishes. Clarified cell lysates from 12-h serum-starved cells were used for Rho activity assay, according to the manufacturer’s instructions (Cytoskeleton). To confirm equal loading of proteins from each sample, 40 µl of total cell lysate from each sample was blotted with β-actin Ab before binding to GST-tagged Rhotekin RBD protein.

Immunoblotting analysis

Immunoblotting analysis was conducted, as described previously, with some modification (39). Briefly, cells (3.0 x 105 cells/well) were plated in each well of a 12-well tissue culture plate and incubated in serum-free medium overnight before use. Following stimulation, the cells were lysed in lysis buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT, 0.5% Triton X-100, and 1x protease inhibitor mixture set I), resolved on 10% SDS-PAGE, and blotted to nitrocellulose membranes. The membranes were probed with primary Abs at 4°C overnight and incubated with HRP-conjugated secondary Abs for 1 h at room temperature. Proteins were visualized by ECL (Amersham Biosciences), according to the manufacturer’s instructions. Equal loading of proteins in each lane was confirmed by Ponceau S staining or reprobed with corresponding Abs against the native proteins or β-actin Ab (17).

Statistical analysis

All data are presented as means ± SEM from three or more separate experiments. The means were analyzed using ANOVA for multiple comparisons. When ANOVA indicated significance, the Tukey-Kramer honestly significant difference test for all pairs was used to compare groups. All data were analyzed using JMP (version 5; SAS Institute) statistical software for the Macintosh.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Effect of apoptotic cells or mAb217 on TGF-β production

To pursue the mechanisms by which apoptotic cells or mAb217 induced TGF-β production in a manner that avoided autostimulation by TGF-β itself, we made stable cell lines that were unresponsive to TGF-β by transfecting truncated TGF-β receptor II (or empty vector as control) constructs into 3T3-L1 cells and RAW 264 cells (9) to block the paracrine and autocrine effects from TGF-β (40, 41). Blockade of TGF-β signaling was verified using TGF-β-responsive luciferase reporter SBE-luc assay. As shown in Fig. 1A, 3T3TβRII cells with truncated TGF-β receptor II did not respond to TGF-β stimulation. Moreover, incubation of these cells with apoptotic Jurkat cells or mAb217 resulted in reduced amounts of TGF-β in the conditioned medium (Fig. 1B) relative to similarly treated 3T3V cells, supporting the supposition that in the normal circumstance, the TGF-β that was induced by apoptotic cells could indeed provide positive autostimulation feedback with enhanced overall production of the mediator.


Figure 1
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 1. Apoptotic cells or mAb217 induce TGF-β production in 3T3-L1 cells. A, 3T3-L1 cells stably transfected with truncated TGF-β receptor II (3T3TβRII) or empty vector (3T3V) were transiently cotransfected with SBE-luc and pSV-β galactosidase constructs. After 48 h, the cells were incubated in the presence of TGF-β (10 ng/ml) for 18 h. The luciferase assays, which were normalized to β-galactosidase, are expressed as fold enhancement. *, Significantly different from 3T3V cells stimulated with TGF-β. B, 3T3V and 3T3TβRII cells were cultured in the presence of mAb217 (100 µg), isotype IgM control (100 µg), apoptotic Jurkat cells (ApoJ), or viable Jurkat cells (ViableJ) for 18 h. Total TGF-β in the conditioned medium was analyzed by ELISA. *, Significantly different from 3T3V cells.

 
Effect of apoptotic cells or mAb217 on TGF-β mRNA expression

As previously described and as shown in Fig. 1, interaction of nonprofessional or professional phagocytes with apoptotic cells (or stimulation with mAb217) induces the production of TGF-β (6, 9, 34). In the present study, apoptotic cells or mAb217 were each shown to induce TGF-β mRNA expression, detectable at 1 h and reaching a plateau from 2 h in 3T3TβRII cells (Fig. 2A). As expected, TGF-β mRNA expression was significantly inhibited by actinomycin D, but not by the protein synthesis inhibitor, cycloheximide, suggesting that new protein synthesis was not required for the induction of TGF-β transcription (Fig. 2B). To rule out the possibility that the increase in TGF-β mRNA was caused by enhancement of TGF-β message stability, 3T3TβRII cells were first treated with PMA (100 nM) overnight to increase the steady-state TGF-β mRNA level, and then washed and treated with actinomycin D (10 µg/ml) in the absence or presence of mAb217. The remaining TGF-β mRNA level after actinomycin D treatment was measured using relative quantitative RT-PCR. As shown in Fig. 2C, mAb217 did not affect TGF-β mRNA stability. These findings suggest that the up-regulation is at the level of transcription.


Figure 2
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 2. Effect of apoptotic Jurkat cells or mAb217 on TGF-β mRNA levels. A, 3T3TβRII cells were cultured in the presence of viable Jurkat cells, apoptotic cells, isotype IgM (100 µg/ml), or mAb217 (100 µg/ml) for the time indicated; B, 3T3TβRII cells were pretreated with the indicated concentrations of actinomycin D (AcD) or cycloheximide (CHX) for 1 h, before stimulation for 4 h; C, 3T3TβRII cells were cultured in the presence of PMA (100 nM) overnight to increase the steady-state TGF-β mRNA level, and then the cells were incubated with actinomycin D (10 µg/ml) in the presence or absence of mAb217 (100 µg/ml) for the time indicated. TGF-β mRNA levels were analyzed by relative quantitative RT-PCR.

 
Requirement for MAPKs in apoptotic cell-induced transcriptional up-regulation of TGF-β production

When 3T3TβRII cells were stimulated with apoptotic Jurkat cells (data not shown) or mAb217, phosphorylation of p38 MAPK, ERK, and JNK was shown to be increased with time, reaching a maximum at 15 min for p38 MAPK and ERK, and 30 min for JNK (Fig. 3A). To examine involvement of these MAPKs in the TGF-β production, 3T3TβRII cells were pretreated with SB 203580, a specific p38 MAPK inhibitor; PD 98059, a specific MEK-1 inhibitor; and JNK inhibitor II for 1 h, and then incubated with apoptotic Jurkat cells or mAb217 for 18 h. As shown in Fig. 3, B and C, both TGF-β protein and enhanced mRNA production were reduced by all three inhibitors at concentrations shown to be effective in previous work and without toxicity (17, 42). These findings suggest that MAPKs might play important roles in apoptotic cell-induced TGF-β transcription.


Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 3. Roles of MAPKs in apoptotic cell or mAb217-induced TGF-β production. A, 3T3TβRII cells were stimulated with mAb217 (100 µg/ml) for the time indicated; total cell lysates were immunoblotted for phospho-p38 MAPK, phospho-ERK, and phospho-JNK. B, 3T3TβRII cells were pretreated with SB 203580 (10 µM), PD 98059 (30 µM), or JNK inhibitor II (30 µM) for 1 h, and then stimulated with apoptotic Jurkat cells (upper panel) or mAb217 (lower panel) for 18 h. Total TGF-β in the conditioned medium was measured by ELISA. *, Significantly different from apoJ or mAb217 alone. C, 3T3TβRII cells were pretreated with SB 203580 (10 µM), PD 98059 (30 µM), or JNK inhibitor II (30 µM) for 1 h, and then stimulated with apoptotic cells (upper panel) or mAb217 (lower panel) for 4 h. TGF-β mRNA level was analyzed by relative quantitative RT-PCR. Ratios of TGF-β and 18S rRNA were measured using densitometric analysis. *, Significantly different from apoJ alone.

 
Involvement of RhoA activation in apoptotic cell-induced TGF-β translation

Small GTP-binding proteins of the Rho family have been found to play an important role in efferocytosis of apoptotic cells (4, 43, 44, 45, 46). Shown in Fig. 4, A and B, is the activation of RhoA in 3T3TβRII cells after exposure to apoptotic Jurkat cells or mAb217. There was no change in the total levels of Rho in the cells over the time course of the experiments (data not shown). The Rho activation was completely inhibited by C3 transferase (Fig. 4B). Consistent with a role for Rho in synthesis of TGF-β, C3 transferase suppressed its production (Fig. 4C). However, blockade of Rho activation did not affect TGF-β mRNA expression (Fig. 4D), suggesting that Rho acts at a posttranscriptional step.


Figure 4
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 4. Requirement for RhoA in apoptotic cell or mAb217-induced TGF-β production. A, 3T3TβRII cells were stimulated with mAb217 (100 µg/ml) for the time indicated, and the levels of activated Rho were determined (see Materials and Methods); B, 3T3TβRII cells were preincubated with C3 transferase (0.3 µg/ml) for 48 h and then stimulated with apoptotic Jurkat cells or mAb217 for 30 min. C, 3T3TβRII cells were preincubated with C3 transferase (0.3 µg/ml) for 48 h and then stimulated with mAb217 for 18 h; TGF-β in the conditioned medium was measured by ELISA. *, Significantly different from mAb217 alone. D, 3T3TβRII cells were preincubated with the indicated concentrations of C3 transferase for 48 h and then stimulated with mAb217 for 4 h; TGF-β mRNA levels were analyzed by relative quantitative RT-PCR.

 
Effect of apoptotic cells on TGF-β translation through RhoA/PI3K/Akt/mTOR/eIF4E

To examine the mechanisms by which translational regulation of TGF-β occurred, 3T3TβRII cells were stimulated with mAb217, and phosphorylation of translation initiator factor eIF4E was determined. As shown in Fig. 5A, phosphorylated eIF4E became detectable at 5 min and reached maximum at 30 min after stimulation. Importantly, the phosphorylation was inhibited by C3 transferase, and this was further confirmed by overexpression of the dominant-negative RhoAN19. Moreover, overexpression of the constitutively active RhoAV14 increased phosphorylation of eIF4E, supporting a requirement of RhoA for TGF-β protein translation (Fig. 5B).


Figure 5
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 5. Requirement for Rho activation in mAb217-induced Akt and eIF4E phosphorylation. A, 3T3TβRII cells were stimulated with mAb217 (100 µg/ml) for the time indicated, and total cell lysates were immunoblotted for phospho-eIF4E. B, 3T3TβRII cells were preincubated with the indicated concentrations of C3 transferase for 48 h and then stimulated with mAb217 for 30 min (upper panel). The 3T3TβRII cells were transiently transfected with empty vector, dominant-negative RhoA N19, or constitutively active RhoA V14. After 48 h, the cells were incubated in the presence or absence of mAb217 for 30 min (lower panel). Total cell lysates were immunoblotted for phospho-Akt or phospho-eIF4E.

 
It has been reported that PI3K, Akt, and mTOR can act upstream of eIF4E (reviewed in Ref. 47). In addition to activation of MAPKs, apoptotic cell or mAb217 each stimulate phosphorylation of Akt (time course not shown) and, as depicted in Fig. 5B, this was inhibited by C3 transferase. Accordingly, when 3T3TβRII cells were treated with the PI3K inhibitors wortmannin or LY 294002 for 1 h before stimulation, phosphorylation of both Akt and eIF4E was inhibited (Fig. 6). Moreover, constitutively active RhoAV14 increased phosphorylation of Akt and eIF4E (Fig. 5B, lower panel).


Figure 6
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 6. PI3K and Akt activation are downstream of RhoA. A, 3T3TβRII cells were pretreated with the indicated concentrations of wortmannin (upper panel) or LY 294002 (lower panel) for 1 h, and then stimulated with mAb217 (100 µg/ml) for 30 min (immunoblotting) or 4 h (TGF-β mRNA). Phospho-Akt and phospho-eIF4E were examined by immunoblotting, and TGF-β mRNA levels were analyzed using relative quantitative RT-PCR. B, 3T3TβRII cells were pretreated with wortmannin (Wort, 100 nM) or LY 294002 (LY, 100 µM) for 1 h, and then stimulated with viable or apoptotic Jurkat cells for 30 min. Total cell lysates were immunoblotted for phospho-eIF4E. Ratios of p-eIF4E and β-actin were measured densitometrically. *, Significantly different from apoJ alone.

 
It has been shown that mTOR is an important mediator downstream of PI3K/Akt for eIF4E phosphorylation (47, 48). Consistent with these findings, rapamycin inhibited mAb217-induced mTOR phosphorylation, as expected, but also blocked phosphorylation of eIF4E (Fig. 7A). By contrast, mTOR phosphorylation was not altered by the MAPK inhibitors SB 203580 and PD 98059, or JNK inhibitor II (Fig. 7A). A role for the PI3K/Akt/mTOR pathway in TGF-β translation was supported by finding that the PI3K and mTOR inhibitors were able to block the production of TGF-β protein, but had no effect on levels of mRNA (Fig. 7, B and C). Collectively, these findings suggest that apoptotic cells regulate TGF-β translation through activation of RhoA/PI3K/Akt/mTOR/eIF4E.


Figure 7
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 7. RhoA/PI3K/mTOR pathways are involved in TGF-β protein production. A, 3T3TβRII cells were pretreated with indicated concentrations of rapamycin overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 50 µM), JNK inhibitor II (JNKII, 50 µM), wortmannin (Wort, 100 nM), or LY 294002 (LY, 100 µM) for 1 h, and then stimulated with mAb217 (100 µg/ml) for 30 min. Total cell lysates were immunoblotted for phospho-mTOR and phospho-eIF4E. B, 3T3TβRII cells were pretreated with rapamycin (100 nM) overnight, and wortmannin (100 nM) or LY 294002 (50 µM) for 1 h, and then stimulated with apoptotic Jurkat cells for 18 h. Total TGF-β in the conditioned medium was analyzed by ELISA. *, Significantly different from apoJ alone. C, 3T3TβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and wortmannin (100 nM) or LY 294002 (100 µM) for 1 h, and then stimulated with apoptotic Jurkat cells for 4 h. TGF-β mRNA levels were analyzed using relative quantitative RT-PCR. Ratios of TGF-β and 18S rRNA were measured densitometrically.

 
Apoptotic cells or mAb217 regulate TGF-β production via unique signal pathways

PMA and LPS are both able to stimulate TGF-β production (7, 49, 50). As shown in Fig. 8A, PMA was found to induce increased levels of TGF-β protein in our system in a fashion that was inhibited by blockade of the MAPKs, but not by wortmannin or rapamycin. As expected, the MAPK inhibitors also prevented the up-regulation of TGF-β mRNA in response to PMA (Fig. 8B), but, in this case, no effect of wortmannin or rapamycin was seen. PMA has been reported to regulate protein translation through p38 MAPK-mediated eIF4E phosphorylation (51, 52, 53) and, as shown in Fig. 8C, both SB 203580 and JNK inhibitor II did block PMA-induced eIF4E phosphorylation. It appears, therefore, that p38 MAPK, ERK, and JNK are involved in both TGF-β transcription and possibly translation induced by PMA, but that the PI3K and mTOR pathways are not required for this stimulus.


Figure 8
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 8. Effect of inhibitors on PMA-induced TGF-β production. A, 3T3TβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 30 µM), JNK inhibitor II (JNKII, 30 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with PMA (100 nM) for 18 h. Total TGF-β in the conditioned medium was analyzed by ELISA. *, Significantly different from PMA alone. B, 3T3TβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 50 µM), JNK inhibitor II (JNKII, 50 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with PMA (100 nM) for 4 h. TGF-β mRNA levels were analyzed using relative quantitative RT-PCR. C, 3T3TβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 50 µM), JNK inhibitor II (JNKII, 50 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with PMA (100 nM) for 30 min. Total cell lysates were immunoblotted for phospho-eIF4E.

 
Similar to PMA stimulation, LPS-induced TGF-β protein production was inhibited by SB 203580, PD 98059, and JNK inhibitor II, but not by wortmannin or rapamycin (Fig. 9A). However, LPS-induced TGF-β mRNA expression was only substantially blocked by the p38 MAPK inhibitor, SB 203580 (Fig. 9B). Surprisingly, LPS-induced eIF4E phosphorylation was inhibited by PD 98059 (MEK inhibitor) and JNK inhibitor II, but not by SB 203580, wortmannin, or rapamycin (Fig. 9C). These findings suggest the following: 1) TGF-β production in response to different stimuli is differently regulated (Table I); 2) apoptotic cells or mAb217 induce TGF-β production through unique signaling pathways, by which p38 MAPK, ERK, and JNK are involved in transcription, and RhoA/PI3K/Akt/mTOR/eIF4E are involved in translation (Fig. 10).


Figure 9
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 9. Effect of inhibitors on LPS-induced TGF-β production. A, RAWTβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 30 µM), JNK inhibitor II (JNKII, 30 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with LPS (100 ng/ml) for 18 h. Total TGF-β in the conditioned medium was analyzed by ELISA. *, Significantly different from LPS alone. B, RAWTβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 50 µM), JNK inhibitor II (JNKII, 50 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with LPS (100 ng/ml) for 4 h. TGF-β mRNA levels were analyzed using relative quantitative RT-PCR. C, RAWTβRII cells were pretreated with rapamycin (Rapa, 100 nM) overnight, and SB 203580 (SB, 10 µM), PD 98059 (PD, 50 µM), JNK inhibitor II (JNKII, 50 µM), or wortmannin (Wort, 100 nM) for 1 h, and then stimulated with LPS (100 ng/ml) for 30 min. Total cell lysates were immunoblotted for phospho-eIF4E.

 

View this table:
[in this window]
[in a new window]

  		Table I. Comparison of kinases and signal pathways involved in TGF-β production

 

Figure 10
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 10. Summary of the mechanisms by which apoptotic cells or mAb217 induce TGF-β production. Apoptotic cells or mAb217 up-regulate TGF-β mRNA expression through p38 MAPK, ERK, and JNK, and enhance protein translation through RhoA/PI3K/Akt/mTOR/eIF4E signaling pathway.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The ability of apoptotic cells to signal for their quiet, noninflammatory, and nonimmunogenic removal in vivo is critical for normal tissue homeostasis and for resolution of inflammation. Just as there is considerable redundancy in the recognition and removal receptors and pathways for apoptotic cells, it seems likely that the anti-inflammatory effects are also mediated by various separate mechanisms. One of these is the selective stimulation by apoptotic cells of the anti-inflammatory and anti-immunogenic mediator, TGF-β. Thus, in previous studies (8, 22), we have shown that the ability of PS-exposing apoptotic cells or PS liposomes to block ongoing pulmonary inflammation or adaptive immunity was significantly dependent on the production of active TGF-β.

To explore the signaling mechanisms by which apoptotic cells induce TGF-β production, it was first necessary to rule out the autocrine- and paracrine-stimulating effects of TGF-β itself. Accordingly, we set up a cell culture system using cells stably transfected with the dominant-negative, truncated TGF-β receptor II. These were shown not to respond to added TGF-β and, as expected, stimulation with apoptotic cells showed lower overall levels of TGF-β produced. This observation supports the presence of autocrine/paracrine effects of TGF-β in enhancing the amounts of the molecule normally generated by apoptotic cells. The mAb217, which was raised against PS-recognizing macrophages, binds to and activates cells in a fashion that mimics exactly the effects of apoptotic cells in terms of efferocytosis and the generation of anti-inflammatory mediators (7, 22, 38). Unfortunately, however, attempts by us and a number of other laboratories have to date been unsuccessful in clearly identifying the Ag(s) with which it interacts. It was used in this study as an adjunct to stimulation with apoptotic cells to initiate TGF-β production without the complexities of adding whole cells into the system. In all cases, the stimulating effects of mAb217 and intact apoptotic cells were qualitatively identical, although, as expected, not always in quantity or exact time course.

We demonstrated that apoptotic cells or mAb217 increased total cellular levels of TGF-β mRNA without affecting its stability. Furthermore, the up-regulated TGF-β transcription was inhibited by SB 203580, PD 98059, and JNK inhibitor II, suggesting the involvement of all three MAPKs (p38 MAPK, ERK, and JNK). Notably, each individual inhibitor almost completely suppressed protein or message expression. Presumably, TGF-β mRNA level is not proportionally related to TGF-β protein, and vice versa (54). TGF-β contains predicted AP-1, Egr-1, and SP-1 binding sites in its promoter regions (41, 55, 56, 57, 58). The AP-1-type proteins mediating this induction may act at one or more AP-1 sites in the two promoters of TGF-β gene and three putative, overlapping AP-1 binding sites ~200 bp downstream of TGF-β (52, 59, 60). Consistent with these, we have observed that blockade of mAb217-induced ERK and JNK phosphorylation inhibited phospho-c-jun, although, surprisingly, SB 203580 increased mAb217-induced phospho-c-jun (data not shown). The role of p38 MAPK in regulation of gene expression was not well understood, although transcriptional factors such as activating transcription factor-2, serum response factor accessory protein-1, and CCAAT enhancer-binding protein-β are known as substrates of p38 MAPK (61). It is important to note that Otsuka et al. (62, 63) have earlier reported that PS liposomes induce TGF-β production with a requirement for ERK and PI3K. However, they did not address possible selective effects on transcription and translation.

The Rho family of small GTPases, including Rho, Rac, and Cdc42, is involved in regulation of a variety of cellular functions, such as cell migration and adhesion, proliferation, vesicle trafficking, bacterial ingestion, and inflammation (64, 65, 66, 67). Interaction of apoptotic cells initiates a delayed activation of Rho in responding cells, and this is known to negatively regulate subsequent efferocytosis (4, 46, 68, 69) (S. Gardai, unpublished observations). Accordingly, we then investigated the possible involvement of Rho in apoptotic cell-induced TGF-β production. Inactivation of RhoA by C3 transferase inhibited apoptotic cell or mAb217-induced TGF-β protein production, but did not affect TGF-β mRNA expression. These findings suggested that posttranscriptional regulation of TGF-β generation is another important control point in regulating the activity of this anti-inflammatory mediator. Further exploration of the downstream effectors leading to TGF-β translation revealed that Rho inhibition resulted in lower levels of Akt and eIF4E phosphorylation.

The mTOR is a central regulator of translation and cell proliferation (70, 71, 72). Two major substrates for mTOR are the serine/threonine kinase p70S6K and 4E-binding protein-1 (4EBP-1). Phosphorylation of 4EBP-1 by mTOR results in release of the cap-binding protein translation initiation factor, eukaryotic initiation factor (eIF4E) (47, 73), which is inactive when bound to hypophosphorylated 4EBP-1. Moreover, eIF4E activity is also regulated by phosphorylation and enhances translation rates of cap-containing mRNAs (74), which include TGF-β (54, 72, 75, 76, 77). The upstream regulator of mTOR in this circumstance appears to be PI3K/Akt (48, 72). PI3K has been reported to be upstream of Rac and Rho (78, 79). In contrast, RhoA also has been shown to prevent myoblast death by inducing the PI3K/Akt pathway (80). In the present study, we suggest that PI3K is a downstream signal mediator from Rho, which then leads to apoptotic cell-induced TGF-β translation through Akt/mTOR/eIF4E. TGF-β itself is known to activate Rho (81, 82, 83, 84); however, this was avoided by use of the 3T3TβRII cells or RAWTβRII cells (Fig. 9). Positive or negative involvement of RhoA in TGF-β production has been reported (85, 86). Our findings suggest that the mechanisms leading to TGF-β regulation might be cell type and stimulus dependent.

MAPKs (p38 MAPK, ERK, and JNK) have been shown to regulate cytokine production at both transcription and translation (17, 87, 88, 89, 90, 91, 92). Intriguingly, when we examined a potential role for p38 MAPK, ERK, or JNK in induction of TGF-β to nonapoptotic cell stimuli PMA or LPS, we did indeed find evidence of their involvement in its translational regulation via eIF4E (51, 53). However, apoptotic cell-induced TGF-β translation appears to be regulated independent of p38 MAPK, ERK, and JNK. Thus, in the present study, we compared apoptotic cells or mAb217 with PMA and LPS for stimulation of TGF-β production. Although all three stimuli activated p38 MAPK, ERK, and JNK, the outcome of the same kinase activation was entirely different (Table I).

These experiments have begun to address the signal pathways involved in enhanced transcription and translation of TGF-β in response to apoptotic cells. Other points of regulation most likely include secretion and extracellular activation of the molecule. Of note, an earlier study in vivo (8) suggested that the administration of apoptotic cells to an ongoing inflammatory site induced an immediate release of TGF-β that was not dependent on protein synthesis, suggesting that, indeed, apoptotic cell recognition might enhance TGF-β liberation from the cell. There are many potential mechanisms by which latent TGF-β may be activated, but, at this point, a possible role for the interaction of the apoptotic cell in this process has not been addressed. These two steps in the process of achieving functional TGF-β are areas for important future research. It will also be critical to sort out the contribution of the various PS-recognizing receptors and bridge molecules involved in its production, release, and activation, just as it has now become equally important to sort out their various contributions to the uptake and clearance process.

In summary, these studies show that apoptotic cells up-regulate TGF-β mRNA expression through p38 MAPK, ERK, and JNK, and enhance protein translation through a newly defined PSRS/RhoA/PI3K/Akt/mTOR/eIF4E signaling pathway (Fig. 10). The present findings demonstrate that the mechanisms leading to apoptotic cell-induced TGF-β production can be distinguished from other stimuli.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants HL81151, GM61031, AI058228, and HL34303. C.G.F.-d.-L. is recipient of Long-Term Fellowship LT-00606-2002 from Human Frontier Science Program. Back

2 Address correspondence and reprint requests to Dr. Peter M. Henson, Program in Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail address: hensonp{at}njc.org Back

3 Abbreviations used in this paper: PS, phosphatidylserine; 4EBP-1, 4E-binding protein-1; eIF4E, eukaryotic initiation factor 4E; mTOR, mammalian target of rapamycin; PSRS, PS recognition structure; SBE, Smad-binding elements. Back

Received for publication January 14, 2008. Accepted for publication July 3, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. DeCathelineau, A. M., P. M. Henson. 2003. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem. 39: 105-117. [Medline]
  2. Gardai, S. J., D. L. Bratton, C. A. Ogden, P. M. Henson. 2006. Recognition ligands on apoptotic cells: a perspective. J. Leukocyte Biol. 79: 896-903. [Abstract/Free Full Text]
  3. Gardai, S. J., K. A. McPhillips, S. C. Frasch, W. J. Janssen, A. Starefeldt, J. E. Murphy-Ullrich, D. L. Bratton, P. A. Oldenborg, M. Michalak, P. M. Henson. 2005. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321-334. [Medline]
  4. Morimoto, K., W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y. Q. Xiao, J. A. Kench, P. M. Henson, R. W. Vandivier. 2006. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol. 176: 7657-7665. [Abstract/Free Full Text]
  5. Vandivier, R. W., P. M. Henson, I. S. Douglas. 2006. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129: 1673-1682. [Medline]
  6. Fadok, V. A., D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, P. M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101: 890-898. [Medline]
  7. Freire-de-Lima, C. G., Y. Q. Xiao, S. J. Gardai, D. L. Bratton, W. P. Schiemann, P. M. Henson. 2006. Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281: 38376-38384. [Abstract/Free Full Text]
  8. Huynh, M. L., V. A. Fadok, P. M. Henson. 2002. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest. 109: 41-50. [Medline]
  9. McDonald, P. P., V. A. Fadok, D. Bratton, P. M. Henson. 1999. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J. Immunol. 163: 6164-6172. [Abstract/Free Full Text]
  10. Chin, B. Y., I. Petrache, A. M. Choi, M. E. Choi. 1999. Transforming growth factor β1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J. Biol. Chem. 274: 11362-11368. [Abstract/Free Full Text]
  11. Dennler, S., M. J. Goumans, P. ten Dijke. 2002. Transforming growth factor β signal transduction. J. Leukocyte Biol. 71: 731-740. [Abstract/Free Full Text]
  12. Feng, X. H., R. Derynck. 2005. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell. Dev. Biol. 21: 659-693. [Medline]
  13. Hartsough, M. T., K. M. Mulder. 1997. Transforming growth factor-β signaling in epithelial cells. Pharmacol. Ther. 75: 21-41. [Medline]
  14. Huang, Y., D. Hutter, Y. Liu, X. Wang, M. S. Sheikh, A. M. Chan, N. J. Holbrook. 2000. Transforming growth factor-β1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities. J. Biol. Chem. 275: 18234-18242. [Abstract/Free Full Text]
  15. Shi, Y., J. Massague. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685-700. [Medline]
  16. Derynck, R., Y. E. Zhang. 2003. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584. [Medline]
  17. Xiao, Y. Q., K. Malcolm, G. S. Worthen, S. Gardai, W. P. Schiemann, V. A. Fadok, D. L. Bratton, P. M. Henson. 2002. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-β. J. Biol. Chem. 277: 14884-14893. [Abstract/Free Full Text]
  18. Fadok, V. A., D. R. Voelker, P. A. Campbell, J. J. Cohen, D. L. Bratton, P. M. Henson. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148: 2207-2216. [Abstract]
  19. Martin, S. J., C. P. Reutelingsperger, A. J. McGahon, J. A. Rader, R. C. van Schie, D. M. LaFace, D. R. Green. 1995. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182: 1545-1556. [Abstract/Free Full Text]
  20. Fadok, V. A., D. L. Bratton, L. Guthrie, P. M. Henson. 2001. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J. Immunol. 166: 6847-6854. [Abstract/Free Full Text]
  21. Fadok, V. A., A. de Cathelineau, D. L. Daleke, P. M. Henson, D. L. Bratton. 2001. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J. Biol. Chem. 276: 1071-1077. [Abstract/Free Full Text]
  22. Hoffmann, P. R., J. A. Kench, A. Vondracek, E. Kruk, D. L. Daleke, M. Jordan, P. Marrack, P. M. Henson, V. A. Fadok. 2005. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J. Immunol. 174: 1393-1404. [Abstract/Free Full Text]
  23. Park, D., A. C. Tosello-Trampont, M. R. Elliott, M. Lu, L. B. Haney, Z. Ma, A. L. Klibanov, J. W. Mandell, K. S. Ravichandran. 2007. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450: 430-434. [Medline]
  24. Miyanishi, M., K. Tada, M. Koike, Y. Uchiyama, T. Kitamura, S. Nagata. 2007. Identification of Tim4 as a phosphatidylserine receptor. Nature 450: 435-439. [Medline]
  25. Kobayashi, N., P. Karisola, V. Pena-Cruz, D. M. Dorfman, M. Jinushi, S. E. Umetsu, M. J. Butte, H. Nagumo, I. Chernova, B. Zhu, et al 2007. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27: 927-940. [Medline]
  26. Santiago, C., A. Ballesteros, L. Martinez-Munoz, M. Mellado, G. G. Kaplan, G. J. Freeman, J. M. Casasnovas. 2007. Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds. Immunity 27: 941-951. [Medline]
  27. Savill, J., C. Gregory. 2007. Apoptotic PS to phagocyte TIM-4: eat me. Immunity 27: 830-832. [Medline]
  28. Park, S. Y., M. Y. Jung, H. J. Kim, S. J. Lee, S. Y. Kim, B. H. Lee, T. H. Kwon, R. W. Park, I. S. Kim. 2008. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 15: 192-201. [Medline]
  29. Akakura, S., S. Singh, M. Spataro, R. Akakura, J. I. Kim, M. L. Albert, R. B. Birge. 2004. The opsonin MFG-E8 is a ligand for the alphavβ5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp. Cell Res. 292: 403-416. [Medline]
  30. Balasubramanian, K., J. Chandra, A. J. Schroit. 1997. Immune clearance of phosphatidylserine-expressing cells by phagocytes: the role of β2-glycoprotein I in macrophage recognition. J. Biol. Chem. 272: 31113-31117. [Abstract/Free Full Text]
  31. Hall, M. O., M. S. Obin, M. J. Heeb, B. L. Burgess, T. A. Abrams. 2005. Both protein S and Gas6 stimulate outer segment phagocytosis by cultured rat retinal pigment epithelial cells. Exp. Eye Res. 81: 581-591. [Medline]
  32. Hanayama, R., M. Tanaka, K. Miwa, A. Shinohara, A. Iwamatsu, S. Nagata. 2002. Identification of a factor that links apoptotic cells to phagocytes. Nature 417: 182-187. [Medline]
  33. Ishimoto, Y., K. Ohashi, K. Mizuno, T. Nakano. 2000. Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. J. Biochem. 127: 411-417. [Abstract/Free Full Text]
  34. Fadok, V. A., D. L. Bratton, D. M. Rose, A. Pearson, R. A. Ezekewitz, P. M. Henson. 2000. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405: 85-90. [Medline]
  35. Bose, J., A. D. Gruber, L. Helming, S. Schiebe, I. Wegener, M. Hafner, M. Beales, F. Kontgen, A. Lengeling. 2004. The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J. Biol. 3: 15[Medline]
  36. Mitchell, J. E., M. Cvetanovic, N. Tibrewal, V. Patel, O. R. Colamonici, M. O. Li, R. A. Flavell, J. S. Levine, R. B. Birge, D. S. Ucker. 2006. The presumptive phosphatidylserine receptor is dispensable for innate anti-inflammatory recognition and clearance of apoptotic cells. J. Biol. Chem. 281: 5718-5725. [Abstract/Free Full Text]
  37. Chang, B., Y. Chen, Y. Zhao, R. K. Bruick. 2007. JMJD6 is a histone arginine demethylase. Science 318: 444-447. [Abstract/Free Full Text]
  38. Hoffmann, P. R., A. M. deCathelineau, C. A. Ogden, Y. Leverrier, D. L. Bratton, D. L. Daleke, A. J. Ridley, V. A. Fadok, P. M. Henson. 2001. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155: 649-659. [Abstract/Free Full Text]
  39. Frasch, S. C., J. A. Nick, V. A. Fadok, D. L. Bratton, G. S. Worthen, P. M. Henson. 1998. p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J. Biol. Chem. 273: 8389-8397. [Abstract/Free Full Text]
  40. Van Obberghen-Schilling, E., N. S. Roche, K. C. Flanders, M. B. Sporn, A. B. Roberts. 1988. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J. Biol. Chem. 263: 7741-7746. [Abstract/Free Full Text]
  41. Kim, S. J., K. T. Jeang, A. B. Glick, M. B. Sporn, A. B. Roberts. 1989. Promoter sequences of the human transforming growth factor-β1 gene responsive to transforming growth factor-β1 autoinduction. J. Biol. Chem. 264: 7041-7045. [Abstract/Free Full Text]
  42. Xiao, Y. Q., K. Minami, S. Mue, K. Ohuchi. 1998. Pharmacological analysis of protein kinases responsible for chemotaxis of rat peritoneal neutrophils. Eur. J. Pharmacol. 360: 195-204. [Medline]
  43. Henson, P. M.. 2005. Engulfment: ingestion and migration with Rac, Rho and TRIO. Curr. Biol. 15: R29-R30. [Medline]
  44. Nakaya, M., M. Tanaka, Y. Okabe, R. Hanayama, S. Nagata. 2006. Opposite effects of rho family GTPases on engulfment of apoptotic cells by macrophages. J. Biol. Chem. 281: 8836-8842. [Abstract/Free Full Text]
  45. Niedergang, F., P. Chavrier. 2005. Regulation of phagocytosis by Rho GTPases. Curr. Top. Microbiol. Immunol. 291: 43-60. [Medline]
  46. Tosello-Trampont, A. C., K. Nakada-Tsukui, K. S. Ravichandran. 2003. Engulfment of apoptotic cells is negatively regulated by Rho-mediated signaling. J. Biol. Chem. 278: 49911-49919. [Abstract/Free Full Text]
  47. Mamane, Y., E. Petroulakis, L. Rong, K. Yoshida, L. W. Ler, N. Sonenberg. 2004. eIF4E: from translation to transformation. Oncogene 23: 3172-3179. [Medline]
  48. Schmelzle, T., M. N. Hall. 2000. TOR, a central controller of cell growth. Cell 103: 253-262. [Medline]
  49. Batuman, O. A., A. Ferrero, C. Cupp, S. A. Jimenez, K. Khalili. 1995. Differential regulation of transforming growth factor β-1 gene expression by glucocorticoids in human T and glial cells. J. Immunol. 155: 4397-4405. [Abstract]
  50. Jun, C. D., B. M. Choi, S. Y. Lee, S. S. Kang, H. M. Kim, H. T. Chung. 1994. Nitric oxide inhibits the expression of protein kinase C{delta} gene in the murine peritoneal macrophages. Biochem. Biophys. Res. Commun. 204: 105-111. [Medline]
  51. Rolli-Derkinderen, M., F. Machavoine, J. M. Baraban, A. Grolleau, L. Beretta, M. Dy. 2003. ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J. Biol. Chem. 278: 18859-18867. [Abstract/Free Full Text]
  52. Scotto, L., P. I. Vaduva, R. E. Wager, R. K. Assoian. 1990. Type β1 transforming growth factor gene expression: a corrected mRNA structure reveals a downstream phorbol ester responsive element in human cells. J. Biol. Chem. 265: 2203-2208. [Abstract/Free Full Text]
  53. Wang, X., A. Flynn, A. J. Waskiewicz, B. L. Webb, R. G. Vries, I. A. Baines, J. A. Cooper, C. G. Proud. 1998. The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J. Biol. Chem. 273: 9373-9377. [Abstract/Free Full Text]
  54. Kim, S. J., K. Park, D. Koeller, K. Y. Kim, L. M. Wakefield, M. B. Sporn, A. B. Roberts. 1992. Post-transcriptional regulation of the human transforming growth factor-β1 gene. J. Biol. Chem. 267: 13702-13707. [Abstract/Free Full Text]
  55. Kim, S. J., F. Denhez, K. Y. Kim, J. T. Holt, M. B. Sporn, A. B. Roberts. 1989. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences. J. Biol. Chem. 264: 19373-19378. [Abstract/Free Full Text]
  56. Kim, S. J., A. Glick, M. B. Sporn, A. B. Roberts. 1989. Characterization of the promoter region of the human transforming growth factor-β1 gene. J. Biol. Chem. 264: 402-408. [Abstract/Free Full Text]
  57. McCaffrey, T. A., C. Fu, B. Du, S. Eksinar, K. C. Kent, H. Bush, Jr, K. Kreiger, T. Rosengart, M. I. Cybulsky, E. S. Silverman, T. Collins. 2000. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J. Clin. Invest. 105: 653-662. [Medline]
  58. Yoo, Y. D., C. J. Chiou, K. S. Choi, Y. Yi, S. Michelson, S. Kim, G. S. Hayward, S. J. Kim. 1996. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor β1 gene through an Egr-1 binding site. J. Virol. 70: 7062-7070. [Abstract/Free Full Text]
  59. Kim, S. J., P. Angel, R. Lafyatis, K. Hattori, K. Y. Kim, M. B. Sporn, M. Karin, A. B. Roberts. 1990. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10: 1492-1497. [Abstract/Free Full Text]
  60. Roberts, A. B., S. J. Kim, P. Kondaiah, S. B. Jakowlew, F. Denhez, A. B. Glick, A. G. Geiser, S. Watanabe, T. Noma, R. Lechleider, et al 1990. Transcriptional control of expression of the TGF-βs. Ann. NY Acad. Sci. 593: 43-50. [Medline]
  61. Ono, K., J. Han. 2000. The p38 signal transduction pathway: activation and function. Cell. Signal. 12: 1-13. [Medline]
  62. Otsuka, M., Y. Negishi, Y. Aramaki. 2007. Involvement of phosphatidylinositol-3-kinase and ERK pathways in the production of TGF-β1 by macrophages treated with liposomes composed of phosphatidylserine. FEBS Lett. 581: 325-330. [Medline]
  63. Otsuka, M., S. Tsuchiya, Y. Aramaki. 2004. Involvement of ERK, a MAP kinase, in the production of TGF-β by macrophages treated with liposomes composed of phosphatidylserine. Biochem. Biophys. Res. Commun. 324: 1400-1405. [Medline]
  64. Etienne-Manneville, S., A. Hall. 2002. Rho GTPases in cell biology. Nature 420: 629-635. [Medline]
  65. Grimsley, C. M., J. M. Kinchen, A. C. Tosello-Trampont, E. Brugnera, L. B. Haney, M. Lu, Q. Chen, D. Klingele, M. O. Hengartner, K. S. Ravichandran. 2004. Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. J. Biol. Chem. 279: 6087-6097. [Abstract/Free Full Text]
  66. Kraynack, N. C., D. A. Corey, H. L. Elmer, T. J. Kelley. 2002. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am. J. Physiol. 283: L604-L611.
  67. Schmitz, A. A., E. E. Govek, B. Bottner, L. Van Aelst. 2000. Rho GTPases: signaling, migration, and invasion. Exp. Cell Res. 261: 1-12. [Medline]
  68. Coleman, M. L., M. F. Olson. 2002. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 9: 493-504. [Medline]
  69. Erwig, L. P., K. A. McPhilips, M. W. Wynes, A. Ivetic, A. J. Ridley, P. M. Henson. 2006. Differential regulation of phagosome maturation in macrophages and dendritic cells mediated by Rho GTPases and ezrin-radixin-moesin (ERM) proteins. Proc. Natl. Acad. Sci. USA 103: 12825-12830. [Abstract/Free Full Text]
  70. Halayko, A. J., S. Kartha, G. L. Stelmack, J. McConville, J. Tam, B. Camoretti-Mercado, S. M. Forsythe, M. B. Hershenson, J. Solway. 2004. Phophatidylinositol-3 kinase/mammalian target of rapamycin/p70S6K regulates contractile protein accumulation in airway myocyte differentiation. Am. J. Respir. Cell Mol. Biol. 31: 266-275. [Abstract/Free Full Text]
  71. Mateo-Lozano, S., O. M. Tirado, V. Notario. 2003. Rapamycin induces the fusion-type independent down-regulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation. Oncogene 22: 9282-9287. [Medline]
  72. Rosenwald, I. B.. 2004. The role of translation in neoplastic transformation from a pathologist’s point of view. Oncogene 23: 3230-3247. [Medline]
  73. Wendel, H. G., E. De Stanchina, J. S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, S. W. Lowe. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337. [Medline]
  74. Raught, B., A. C. Gingras. 1999. eIF4E activity is regulated at multiple levels. Int. J. Biochem. Cell Biol. 31: 43-57. [Medline]
  75. Rajasekhar, V. K., E. C. Holland. 2004. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 23: 3248-3264. [Medline]
  76. Ruggero, D., L. Montanaro, L. Ma, W. Xu, P. Londei, C. Cordon-Cardo, P. P. Pandolfi. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10: 484-486. [Medline]
  77. Van der Velden, A. W., A. A. Thomas. 1999. The role of the 5' untranslated region of an mRNA in translation regulation during development. Int. J. Biochem. Cell Biol. 31: 87-106. [Medline]
  78. Ridley, A. J.. 2001. Rho proteins, PI 3-kinases, and monocyte/macrophage motility. FEBS Lett. 498: 168-171. [Medline]
  79. Sharma-Walia, N., P. P. Naranatt, H. H. Krishnan, L. Zeng, B. Chandran. 2004. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J. Virol. 78: 4207-4223. [Abstract/Free Full Text]
  80. Reuveny, M., H. Heller, E. Bengal. 2004. RhoA controls myoblast survival by inducing the phosphatidylinositol 3-kinase-Akt signaling pathway. FEBS Lett. 569: 129-134. [Medline]
  81. Edlund, S., M. Landstrom, C. H. Heldin, P. Aspenstrom. 2002. Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 13: 902-914. [Abstract/Free Full Text]
  82. Masszi, A., C. Di Ciano, G. Sirokmany, W. T. Arthur, O. D. Rotstein, J. Wang, C. A. McCulloch, L. Rosivall, I. Mucsi, A. Kapus. 2003. Central role for Rho in TGF-β1-induced {alpha}-smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol. 284: F911-F924.
  83. Murata, T., S. Arii, A. Mori, M. Imamura. 2003. Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. J. Surg. Res. 114: 64-71. [Medline]
  84. Shen, X., J. Li, P. P. Hu, D. Waddell, J. Zhang, X. F. Wang. 2001. The activity of guanine exchange factor NET1 is essential for transforming growth factor-β-mediated stress fiber formation. J. Biol. Chem. 276: 15362-15368. [Abstract/Free Full Text]
  85. Baccante, G., G. Mincione, M. C. Di Marcantonio, A. Piccirelli, F. Cuccurullo, E. Porreca. 2004. Pravastatin up-regulates transforming growth factor-β1 in THP-1 human macrophages: effect on scavenger receptor class A expression. Biochem. Biophys. Res. Commun. 314: 704-710. [Medline]
  86. Sakata, R., T. Ueno, T. Nakamura, H. Ueno, M. Sata. 2004. Mechanical stretch induces TGF-β synthesis in hepatic stellate cells. Eur. J. Clin. Invest. 34: 129-136. [Medline]
  87. Huttunen, P., T. Hyypia, P. Vihinen, L. Nissinen, J. Heino. 1998. Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes. Virology 250: 85-93. [Medline]
  88. Kaminska, B.. 2005. MAPK signalling pathways as molecular targets for anti-inflammatory therapy: from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754: 253-262. [Medline]
  89. Shin, S. Y., J. H. Lee, B. Min, Y. H. Lee. 2006. The translation inhibitor anisomycin induces Elk-1-mediated transcriptional activation of egr-1 through multiple mitogen-activated protein kinase pathways. Exp. Mol. Med. 38: 677-685. [Medline]
  90. Swantek, J. L., M. H. Cobb, T. D. Geppert. 1997. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor {alpha} (TNF-{alpha}) translation: glucocorticoids inhibit TNF-{alpha} translation by blocking JNK/SAPK. Mol. Cell. Biol. 17: 6274-6282. [Abstract]
  91. Wu, C. Y., H. L. Hsieh, M. J. Jou, C. M. Yang. 2004. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-{kappa}B in interleukin-1β-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J. Neurochem. 90: 1477-1488. [Medline]
  92. Xiao, Y. Q., K. Someya, H. Morita, K. Takahashi, K. Ohuchi. 1999. Involvement of p38 MAPK and ERK/MAPK pathways in staurosporine-induced production of macrophage inflammatory protein-2 in rat peritoneal neutrophils. Biochim. Biophys. Acta 1450: 155-163. [Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiao, Y. Q.
Right arrow Articles by Henson, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, Y. Q.
Right arrow Articles by Henson, P. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS